search icon
Join IDSAJOIN IDSA >> Go to MyIDSAGO TO MYIDSA >>
  • Print
  • ShareThis
  • Text Size

IDSA News Releases

09/20/2016

Infectious Diseases Society of America Statement on United Nations Meeting on Antimicrobial Resistance

Infectious Diseases Society of America (IDSA) Vice President Paul Auwaerter, MD, MBA, FIDSA and Treasurer Helen Boucher, MD, FIDSA will join world leaders gathering tomorrow for an historic United Nations (UN) General Assembly meeting on one of the most urgent public health crises facing our world today—antimicrobial resistance (AMR). More than 500 IDSA members with expertise in AMR stand behind Drs. Auwaerter and Boucher on a petition that will be sent to the UN today in support of a coordinated global response to this global threat. Tomorrow’s high level meeting represents a significant opportunity to drive the action needed to effectively stem the tide of AMR.
09/19/2016

Senate Health, Education, Labor and Pensions Committee Hearing: “Laboratory Testing in the Era of Precision Medicine”

The Infectious Diseases Society of America (IDSA) is pleased that the Senate Health, Education, Labor and Pensions (HELP)” Committee has scheduled the hearing, “Laboratory Testing in the Era of Precision Medicine,” for September 20, 2016.
09/16/2016

People with Hepatitis C Should Be Tested for Hepatitis B Before Starting Antiviral Therapies

All patients beginning hepatitis C (HCV) treatment using direct acting antiviral (DAA) therapies should be assessed for hepatitis B (HBV), according the American Association for the Study of Liver Diseases/Infectious Diseases Society of America Guidance Panel, which provides up-to-date guidance on the treatment of hepatitis C on its website, HCVguidelines.org.
08/10/2016

Patients with TB and HIV Should Receive Prompt Coordinated Treatment for Both Conditions

Tuberculosis (TB) is a leading killer of people with HIV, and providing therapy for both illnesses simultaneously saves lives – according to new guidelines on the treatment of drug-susceptible TB developed jointly by the American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC) and Infectious Diseases Society of America (IDSA). Treatment of TB in the presence of HIV infection is one of several special situations addressed in the new guidelines, published today in the journal Clinical Infectious Diseases.
07/29/2016

Infectious Diseases Experts Stress Importance of Testing and Prevention in Response to Confirmed Local Transmission of Zika Virus

Florida health officials and the Centers for Disease Control and Prevention (CDC) today confirmed local transmission of the Zika virus in a specific area of Dade and Broward Counties in Florida, emphasizing the need for robust, ongoing Zika surveillance and response preparedness wherever Zika-transmitting mosquitos are found in the US. Infectious diseases physicians are urging the public to take measures to protect themselves from contracting the virus while also urging Congress to provide the funding necessary for an appropriate public health response.
07/28/2016

Valley Fever Diagnosis Often Missed

For patients with pneumonia or ongoing influenza-like symptoms who live in or have visited the west or southwest United States, especially Arizona and central California, infectious diseases experts recommend physicians suspect valley fever, an often-overlooked fungal infection. Early diagnosis ensures the best management and reduces unneeded tests and treatment, note updated guidelines released by the Infectious Diseases Society of America (IDSA) and published in the journal Clinical Infectious Disease.
07/19/2016

HCV Guidance Website Updated to Reflect Latest Drug Developments

HCVguidelines.org, a website developed by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) to provide up-to-date guidance on the treatment of hepatitis C (HCV) has updated several sections of the website based on newly available therapies and data.
07/14/2016

Shorter Courses of Antibiotics Safe for Treatment of Patients with Hospital-Acquired, Ventilator-Associated Pneumonia

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) - which account for 20 to 25 percent of hospital-acquired infections - should be treated with shorter courses of antibiotics than they typically are, according to new guidelines released by the Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) and published in the journal Clinical Infectious Diseases.
06/30/2016

Early Diagnosis, Effective Therapy Vital for Treatment of Deadly Invasive Aspergillosis

New therapies are improving care, but early diagnosis remains critical in the effective treatment of invasive aspergillosis, a potentially deadly fungal infection, according to new guidelines released by the Infectious Diseases Society of America (IDSA) and published in the journal Clinical Infectious Diseases.
04/18/2016

IDSA Names Christopher D. Busky, CAE, as the Society’s New CEO

The Society’s next top staffer brings extensive experience in association management and has a track record for organizational leadership representing healthcare professionals.
04/14/2016

New Antibiotic Stewardship Guidelines Focus on Practical Advice for Implementation

Preauthorization of broad-spectrum antibiotics and prospective review after two or three days of treatment should form the cornerstone of antibiotic stewardship programs to ensure the right drug is prescribed at the right time for the right diagnosis. These are among the numerous recommendations included in new guidelines released by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) and published in the journal Clinical Infectious Diseases.
03/31/2016

Presidential Advisory Council on Combating Antibiotic Resistant Bacteria Report

Recommendations from the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria reflect IDSA input.
02/25/2016

HCV Guidance Website Updated to Reflect Latest Drug Developments

The latest release of the guidance reflects several important developments, including the recent approval of the second single-tablet fixed dose combination regimen (elbasvir/grazoprevir) for the treatment of HCV.

| HIVMA | Contact Us

© Copyright IDSA 2016 Infectious Diseases Society of America

Full Site Mobile Site